{
    "nctId": "NCT00746694",
    "briefTitle": "A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)",
    "officialTitle": "Epidemiological Study to Assess the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Pegylated Liposomal Doxorubicin",
    "overallStatus": "COMPLETED",
    "conditions": "Ovarian Neoplasms, Breast Neoplasms, Paresthesia",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 154,
    "primaryOutcomeMeasure": "Number of Participants Who Received Concomitant Treatment Strategies to Manage Palmar-Plantar Erythrodysesthesia (PPE)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women 18 years of age or older.\n* Participants with metastatic breast or ovarian cancer who are receiving treatment with pegylated liposomal doxorubicin.\n* Participants who have given their written consent.\n\nExclusion Criteria:\n\n* Participants who are currently participating in a clinical trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}